Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 4/20 | 0.58 |
| ▸ | KIF11 | P52732 | 5/20 | 0.57 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.55 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.55 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.55 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.55 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.49 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.49 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.49 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2407068 | 0.89 | MAPT (0.58) | PKMKIF11SRD5A1NPC1MAPK13 | |
| SCHEMBL31310679 | 0.89 | MAPT (0.58) | PKMKIF11SRD5A1NPC1MAPK13 | |
| SCHEMBL31310681 | 0.89 | MAPT (0.58) | PKMKIF11SRD5A1NPC1MAPK13 | |
| SCHEMBL3312587 | 0.86 | KIF11 (0.72) | PKMKIF11NPC1MAPK13MAPK12 | |
| SCHEMBL17079530 | 0.86 | HTR5A (0.53) | PKMKIF11SRD5A1CYP1A2CA9 | |
| SCHEMBL4102521 | 0.85 | CA9 (0.62) | PKMKIF11SRD5A1NPC1MAPK13 | |
| SCHEMBL29754281 | 0.85 | CA9 (0.62) | PKMKIF11SRD5A1NPC1MAPK13 | |
| SCHEMBL3309739 | 0.83 | TDP2 (0.60) | PKMKIF11SRD5A1NPC1MAPK13 | |
| SCHEMBL152963 | 0.82 | AHR (0.61) | KIF11PDE3BPDE3ACYP1A2CYP11B1 | |
| SCHEMBL3309677 | 0.82 | KIF11 (0.62) | PKMKIF11NPC1MAPK13MAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3416633-B1 | TETRAHYDROQUINOLINE SUBSTITUTED HYDROXAMIC ACIDS AS SELECTIVE HISTONE DEACETYLASE 6 INHIBITORS | UNIV ILLINOIS (US) | 2025-07-23 | — | — | EP | disclosed |
| EP-3998268-B1 | COMPOUND FOR INHIBITING EGFR KINASE AND PREPARATION METHOD AND USE THEREOF | WIGEN BIOMEDICINE TECH SHANGHAI CO LTD (CN) | 2024-12-18 | — | — | EP | disclosed |
| US-11993598-B2 | Compounds for inhibiting EGFR kinase, preparation methods and uses thereof | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2024-05-28 | — | — | US | disclosed |
| CN-114026090-B | Compound for inhibiting EGFR kinase and preparation method and application thereof | 微境生物医药科技(上海)有限公司 | 2023-01-06 | — | — | CN | disclosed |
| CN-114585616-A | Amide derivatives and their use in medicine | 广东东阳光药业有限公司 | 2022-06-03 | — | — | CN | disclosed |
| EP-3998268-A1 | COMPOUND FOR INHIBITING EGFR KINASE AND PREPARATION METHOD AND USE THEREOF | Wigen Biomedicine Technology (Shanghai) Co., Ltd. (CN) | 2022-05-18 | — | — | EP | disclosed |
| EP-3998268-A1 | COMPOUND FOR INHIBITING EGFR KINASE AND PREPARATION METHOD AND USE THEREOF | Wigen Biomedicine Technology (Shanghai) Co., Ltd. (CN) | 2022-05-18 | — | — | EP | disclosed |
| US-20220081427-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | IMAGO PHARMACEUTICALS, INC. (US) | 2022-03-17 | — | — | US | disclosed |
| CN-114026090-A | Compound for inhibiting EGFR kinase and preparation method and application thereof | 微境生物医药科技(上海)有限公司 | 2022-02-08 | — | — | CN | disclosed |
| US-20210230161-A1 | COMPOUNDS FOR INHIBITING EGFR KINASE, PREPARATION METHODS AND USES THEREOF | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2021-07-29 | — | — | US | disclosed |
| WO-2006068904-A1 | TETRAHYDROQUINOLINE ANALOGUES AS MUSCARINIC AGONISTS | ACADIA PHARMACEUTICALS INC. (US) | 2006-06-29 | — | — | WO | disclosed |
| EP-1461318-B9 | TETRAHYDROQUINOLINE ANALOGUES AS MUSCARINIC AGONISTS | ACADIA PHARM INC (US) | 2005-12-28 | — | — | EP | disclosed |
| US-20050209226-A1 | Neurodegenerative diseases, psychological disorders; e.g. 4-[3-(3a -Cyclopropylmethoxy-8-azabicyclo[3.2.1]oct-8-yl)-2-methylpropyl]-4H-benzo[1.4]oxazin-3-one | ACADIA PHARMACEUTICALS INC. | 2005-09-22 | — | — | US | disclosed |
| EP-1461318-B1 | TETRAHYDROQUINOLINE ANALOGUES AS MUSCARINIC AGONISTS | ACADIA PHARM INC (US) | 2005-09-14 | — | — | EP | disclosed |
| EP-1461318-A2 | TETRAHYDROQUINOLINE ANALOGUES AS MUSCARINIC AGONISTS | Acadia Pharmaceuticals Inc. (US) | 2004-09-29 | — | — | EP | disclosed |
| US-20030176418-A1 | Tetrahydroquinoline analogues as muscarinic agonists | ACADIA PHARMACEUTICALS INC. | 2003-09-18 | — | — | US | disclosed |
| WO-2003057672-A2 | TETRAHYDROQUINOLINE ANALOGUES AS MUSCARINIC AGONISTS | ACADIA PHARMACEUTICALS, INC. (US) | 2003-07-17 | — | — | WO | disclosed |
| EP-0162776-B1 | HETEROCYCLIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND MEDICAMENTS USEFUL AS ALDOSE REDUCTASE INHIBITORS CONTAINING THEM | LABORATOIRES UPSA (FR) | 1989-04-19 | — | — | EP | disclosed |
| US-4755509-A | Heterocyclic aldose reductase inhibitors and methods of using them | Carbipem (FR) | 1988-07-05 | — | — | US | disclosed |
| EP-0162776-A2 | Heterocyclic derivatives, process for their preparation and medicaments useful as aldose reductase inhibitors containing them | LABORATOIRES UPSA (FR) | 1985-11-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210230161-A1 | COMPOUNDS FOR INHIBITING EGFR KINASE, PREPARATION METHODS AND USES THEREOF | EGFR, ERBB2, ERBB4 | PKM 1871/4885KIF11 863/4885SRD5A1 1375/4885 |
| US-20050209226-A1 | Neurodegenerative diseases, psychological disorders; e.g. 4-[3-(3a -Cyclopropylmethoxy-8-azabicyclo[3.2.1]oct-8-yl)-2-methylpropyl]-4H-benzo[1.4]oxazin-3-one | CHRNA4, CHRNA2, CHRNA5 | PKM 2437/4885KIF11 2720/4885SRD5A1 1062/4885 |
| US-20030176418-A1 | Tetrahydroquinoline analogues as muscarinic agonists | CHRM3, CHRM5, CHRM2 | PKM 3106/4885KIF11 3119/4885SRD5A1 1284/4885 |
| US-20220081427-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | CHUK, MAPK6, MAPK3 | PKM 2326/4885KIF11 2308/4885SRD5A1 3980/4885 |
| US-11993598-B2 | Compounds for inhibiting EGFR kinase, preparation methods and uses thereof | EGFR, ERBB2, ERBB4 | PKM 1871/4885KIF11 863/4885SRD5A1 1375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.